Drugs / Hib vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy5 trials | ||||||
| Phase 3 | NCT02992925 Comparator | Nov 2016 → Dec 2017 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02274285 Comparator | Oct 2014 → May 2016 | bacterial meningitis, diphtheria, pertussis, poliomyelitis +1 | Sanofi Pasteur, a Sanofi Company | Completed | Mixed |
| Phase 3 | NCT01580033 Comparator | Apr → Sep 2012 | influenza, meningitis | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 3 | NCT01428908 Comparator | Sep → Dec 2011 | haemophilus infectious disease, meningococcemia | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| — | NCT02133469 Comparator | Jun 2012 → Apr 2014 | nasopharyngeal disorder, streptococcal pneumonia | Centers for Disease Control and Prevention, China | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hib vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02274285 ↗ |
| Modality | Vaccine | “The type b haemophilus influenzal vaccine” NCT01428908 ↗ |
| Route | Intramuscular | “will be administered intramuscularly on the other arm” NCT01428908 ↗ |